Equities

Blueprint Medicines Corp

Blueprint Medicines Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)90.94
  • Today's Change1.61 / 1.80%
  • Shares traded675.19k
  • 1 Year change+77.17%
  • Beta0.5879
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments711945477
Total Receivables, Net433737
Total Inventory213022
Prepaid expenses333518
Other current assets, total------
Total current assets8081,047554
Property, plant & equipment, net116115121
Goodwill, net------
Intangibles, net------
Long term investments57133558
Note receivable - long term------
Other long term assets584915
Total assets1,0491,3501,252
LIABILITIES
Accounts payable4.712.738.33
Accrued expenses140142130
Notes payable/short-term debt000
Current portion long-term debt/capital leases3017--
Other current liabilities, total402212
Total current liabilities215183150
Total long term debt2091220
Total debt2391390
Deferred income tax------
Minority interest------
Other liabilities, total495530132
Total liabilities919835281
SHAREHOLDERS EQUITY
Common stock0.060.060.06
Additional paid-in capital2,4742,3582,250
Retained earnings (accumulated deficit)(2340)(1833)(1275)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.5)(10)(4.13)
Total equity131515971
Total liabilities & shareholders' equity1,0491,3501,252
Total common shares outstanding616059
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.